Chikungunya Virus IgM Porcine-capture

Brand

GENWAY

Overview

Intended Use: The Chikungunya IgM μ-capture ELISA is intended for the qualitative determination of IgM class antibodies to Chikungunya virus in human serum and plasma (citrate). Introduction: Chikungunya virus is an arthropod borne virus of the genus Alphavirus (family Togaviridae). The Alphavirus genus contains at least 24 distinct species. These are lipid-enveloped virions with a diameter of 50 to 60 nm. Alphavirus infections are initiated by the bite of an infected mosquito which results in the deposition of virus in subcutaneous and possibly cutaneous tissues. After an incubation period of 1 to 12 days the Chikungunya fever develops. Chikungunya fever (Chikungunya means ?that which bends up? in reference to the crippling manifestations of the disease) is an acute viral infection characterized by a rapid transition from a state of good health to illness that includes severe arthralgia and fever. Temperature rises abruptly to as high as 40°C and is often accompanied by shaking chills. After a few days fever may abate and recrudesce giving rise to a ?saddleback? fever curve. Arthralgia is polyarticular favoring the small joints and sites of previous injuries and is most intense on arising. Patients typically avoid movement as much as possible. Joints may swell without significant fluid accumulations. These symptoms may last from 1 week to several months and are accompanied by myalgia. The rash characteristically appears on the first day of illness but onset may be delayed. It usually arises as a flush over the face and neck which evolves to a maculopapular or macular form that may be pruritic. The latter lesions appear on the trunk limbs face plams and soles in that order of frequency. Petechial skin lesions have also been noted. Headache photophobia retro-orbitral pain sore throat with objective signs of pharyngitis nausea and vomiting also occur in this setting. Occasionally however persistent arthralgia and polyarthritis (lasting months or even years) do occur sometimes involving joint destruction. Even rarer sequelae include encephalitis and meningoencephalitis with high lethality rates. The virus has major importance in Africa and Asia. From 20% to more than 90% of the population of tropical and subtropical show serologic evidence of infection. Because Aedes mosquitoes are increasingly prevalent in North Africa and South America where the population would be uniformly susceptible to infection the possibility for epidemics is evident. Chikungunya virus infections are imported to central Europe mainly by travellers to tropical and subtropical countries. The presence of virus resp. infection may be identified bySerology: Detection of antibodies by IF ELISAPrinciples of the assay: The qualitative immunoenzymatic determination of IgM-class antibodies to Chikungunya is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microtiter strip wells are precoated with anti human IgM to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample and control material Chikungunya antigen solution is added. After a further washing step a mixture of biotinylated Chikungunya antibody and Streptavidin conjugate is added. After washing the captured Chikungunya-specific immuncomplex is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of Chikungunya-specific IgM antibodies in the patient specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader. Storage and Stability: The reagents are stable up to the expiry date stated on the label when stored at 2. . . 8 °C. Limitations of the Test: Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history symptomatology as well as serological data. In immunosuppremized patients and newborns serological data only have restricted value. References Gerald L. Mandell John E. Bennett Raphael Dolin Principles and practice of Infectious diseases 2005 Chapter 147 1913?1919Patrick Hochedez Staphane Jaureguiberry Monique Debruyne Philippe Bossi Pierre Hausfater Gilles Brucker Francois Bricaire Eric Caumes Chikungunya infection in travellers Emerging Infectios Diseases Vol. 12 No. 10 October 2006 1565-1566F. H. Kayser K. A. Bienz J. Eckert R. M. Zinkernagel Medical Microbiology Stuttgart 2005 440-441

spezie

other

detection target

Chikungunya Virus IgM

pack size

1x96 assay